Phaseline

Targets › CHRM2

CHRM2 (Muscarinic acetylcholine receptor M2): drug programs, companies and trials

18 programs from 17 companies in 125 trials: 45 Phase 3, 30 Phase 4, 29 Phase 2, 21 Phase 1; Other, Genitourinary, Neurology; next expected readout Nov 2026.

Muscarinic receptor for acetylcholine, a neurotransmitter found in the brain, neuromuscular junctions and the autonomic ganglia. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. (UniProt, P08172)

Open in Phaseline: the race on CHRM2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bristol-Myers SquibbTrospium Chloride
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 4Schizophrenia; Bipolar-I Disorder With Mania or Mania With Mixed Features; Bipolar Disorder Type I With Mania or Mania With Mixed Features; Mania …Nov 2026
Bristol-Myers SquibbTrospium Chloride (BMS-986510)
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 4Healthy Volunteers; Psychosis Associated With Alzheimer's Disease; Alzheimer Disease; SchizophreniaNov 2026
University of California, San FranciscoIntravenous TXA
Interleukin-23 inhibitor
ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4Phase 4Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke …Dec 2026
Mackay Memorial HospitalSolifenacin
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 4Effect of Drug; Urinary Bladder, OveractiveDec 2026
Mansoura UniversitySolifenacin succinate
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 4Overactive Bladder (OAB); Nocturnal Enuresis in ChildrenJun 2027
University of AarhusSolifenacin
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 4Urinary Incontinence in ChildrenOct 2027
University of California, DavisOxybutynin
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 3Overactive Bladder SyndromeDec 2026
Bir HospitalSolifenacin Succinate
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 3Ureteral Stent-Related SymptomDec 2026
Ocus Innovation IrelandAtropine
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM1, CHRM2Phase 3MyopiaDec 2027
Central Hospital, Nancy, FranceOxybutynin
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 3Spina BifidaJan 2028
Sherief Abd-Elsalamorphenadrine
Anticholinergic drug with CNS and peripheral activity; used for muscle spasms and pain
CHRM1, CHRM2, CHRM3Phase 3Liver CirrhosisDec 2028
Reinier de Graaf GroepOxybutynin
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 3Breast CancerJan 2029
Zhaoke (Guangzhou) Ophthalmology PharmaceuticalAtropine
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM1, CHRM2Phase 3Myopia; Achalasia; Progressive Myopia; Focus on Axial Length …–
Belfast Health and Social Care TrustAtropine Sulfate
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM1, CHRM2Phase 2MyopiaFeb 2027
Oliver BlanchardDarifenacin
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 2Amyotrophic Lateral SclerosisOct 2027
University Hospital, BordeauxOxybutynin
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 2Male Urogenital DiseasesFeb 2028
AstraZenecaGlycopyrronium
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor inhibitor
CHRM3, CHRM1, CHRM4, CHRM2, CHRM5Phase 2AsthmaMay 2029
University of ArizonaOxybutynin
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 2Obstructive Sleep Apnea–

Conditions

Myopia (17) Schizophrenia (6) Alzheimer Disease (4) Healthy Volunteers (4) Alzheimer's Disease (3) Psychosis Associated With Alzheimer's Disease (3) Nicotine Dependence (3) Progressive Myopia (2) Myopia, Progressive (2) Urinary Incontinence in Children (2) Breast Cancer (2) Psoriasis Vulgaris (2)

Modalities

small molecule (16), protein or peptide (1)

Companies

Bristol-Myers Squibb (2) Zhaoke (Guangzhou) Ophthalmology Pharmaceutical (1) University of Arizona (1) Bir Hospital (1) University of Aarhus (1) Reinier de Graaf Groep (1) Ocus Innovation Ireland (1) University Hospital, Bordeaux (1) University of California, San Francisco (1) Belfast Health and Social Care Trust (1) Mackay Memorial Hospital (1) Central Hospital, Nancy, France (1) Oliver Blanchard (1) AstraZeneca (1) Mansoura University (1) Sherief Abd-Elsalam (1) University of California, Davis (1)

Related targets

CHRM3 (18) CHRM1 (5) ADRB2 (1) AGTR1 (1) IL12B (1) IL23A (1) PDCD1 (1) NR3C1 (1) HTR2A (1) MAP2K1 (1) MAP2K2 (1) MS4A1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.